---
title: "Antimicrobial Resistance Trends in Iraq (2021–2024): National Surveillance Findings and Empirical"
id: "medrxiv-0-temporal-trends-in-antimicrobial-resistance-among-clinically-important"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-0-temporal-trends-in-antimicrobial-resistance-among-clinically-important"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.30.26364389v1?rss=1"
published_at: "2026-10-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Antimicrobial Resistance Trends in Iraq (2021–2024): National Surveillance Findings and Empirical
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-0-temporal-trends-in-antimicrobial-resistance-among-clinically-important
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.30.26364389v1?rss=1)
- **Published At:** 2026-10-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This study performed a retrospective longitudinal analysis of aggregated national antimicrobial resistance (AMR) surveillance data from Iraq covering 2021–2024 to assess temporal changes among clinically important pathogens and implications for empirical therapy and stewardship. - The analysis included 92,338 organism records: **Escherichia coli** 40,496 (43.9%), **Staphylococcus aureus** 24,621 (26.7%), **Klebsiella pneumoniae** 18,223 (19.7%) and **Pseudomonas aeruginosa** 8,998 (9.7%). - Annual resistance proportions were evaluated for clinically relevant antimicrobials; temporal change was characterised using absolute percentage-point changes and exploratory linear regression. - In 2024, ceftriaxone resistance reached 82.9% in **E. coli** and 65.2% in **K. pneumoniae**; ciprofloxacin resistance was 55.4% in E. coli and 57.9% in K. pneumoniae. - **Meropenem** resistance was substantial: 37.4% in K. pneumoniae and 62.3% in P. aeruginosa in 2024, constraining reliance on **carbapenem** escalation when other β-lactam resistance is suspected. - Some resistances declined: amoxicillin–clavulanate resistance in E. coli fell from 83.5% in 2021 to 57.2% in 2024; piperacillin–tazobactam resistance in P. aeruginosa declined from 46.4% to 32.9%. - Several pathogen–antimicrobial combinations displayed marked year-to-year variation; after false discovery rate correction, no temporal trend remained statistically significant. - Authors conclude that resistance to agents central to empirical therapy remains high in Iraq, national trajectories are heterogeneous, and empirical recommendations should integrate regular national and local surveillance rather than single-year antibiograms. - The underlying surveillance data are held by Iraqi health authorities and are not publicly available; access may be considered on request subject to approval and governance. The study used de-identified aggregated data and reported no competing interests.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=L4ASe3twWKpuk63PdnpDUSmPMzRJCU8yAguv7QB3Pj8-1790982116.7251394-1.2.1.1-Ii9xkMRSJe1mz1pcdPBimlZUnN8cfCiHXcK8CmihyBEunRYQIW510XbdBV99i2cs) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.09.30.26364389v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Temporal Trends in Antimicrobial Resistance Among Clinically Important Pathogens in Iraq, 2021–2024: Implications for Empirical Antimicrobial Therapy [ View ORCID Profile](http://orcid.org/0000-0002-6369-296X)Omeed Darweesh, Hemn Ahmed, Haidar Kadhim Al-Jawadi, Ramiar Kamal Kheder, Noor Najim Alwiswasi, Sarah Mohammed Hameed, Hemen Faik Mohammed, [ View ORCID Profile](http://orcid.org/0000-0001-5036-1988)Amanj Ismael Baker Kurdi doi: https://doi.org/10.64898/2026.09.30.26364389 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Omeed Darweesh 1 Al-Kitab University College of Pharmacy; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Omeed%2BDarweesh%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Darweesh%20O&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AOmeed%2BDarweesh%2B) * [ORCID record for Omeed Darweesh](http://orcid.org/0000-0002-6369-296X "Open in new tab") Hemn Ahmed 2 Al Qalam University College; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Hemn%2BAhmed%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ahmed%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHemn%2BAhmed%2B) Haidar Kadhim Al-Jawadi 3 Republic of Iraq Ministry of Health; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Haidar%2B%2BKadhim%2BAl-Jawadi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Al-Jawadi%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHaidar%2B%2BKadhim%2BAl-Jawadi%2B) Ramiar Kamal Kheder 4 University of Raparin College of Science; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ramiar%2B%2BKamal%2BKheder%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kheder%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ARamiar%2B%2BKamal%2BKheder%2B) Noor Najim Alwiswasi 3 Republic of Iraq Ministry of Health; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Noor%2B%2BNajim%2BAlwiswasi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Alwiswasi%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANoor%2B%2BNajim%2BAlwiswasi%2B) Sarah Mohammed Hameed 1 Al-Kitab University College of Pharmacy; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Sarah%2B%2BMohammed%2BHameed%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hameed%20S&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ASarah%2B%2BMohammed%2BHameed%2B) Hemen Faik Mohammed 5 Kirkuk Health Directorate; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Hemen%2B%2BFaik%2BMohammed%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Mohammed%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHemen%2B%2BFaik%2BMohammed%2B) Amanj Ismael Baker Kurdi 6 Strathclyde Institute of Pharmacy and Biomedical Sciences: University of Strathclyde Institute of Pharmacy and Biomedical Sciences * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Amanj%2B%2BIsmael%2BBaker%2BKurdi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kurdi%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAmanj%2B%2BIsmael%2BBaker%2BKurdi%2B) * [ORCID record for Amanj Ismael Baker Kurdi](http://orcid.org/0000-0001-5036-1988 "Open in new tab") * For correspondence: amanj.baker@strath.ac.uk * [Abstract](https://www.medrxiv.org/content/10.64898/2026.09.30.26364389v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1312193/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.09.30.26364389v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1312193/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.09.30.26364389v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1312193/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.09.30.26364389v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1312193/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.09.30.26364389v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1312193/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract To characterise temporal changes in antimicrobial resistance (AMR) among clinically important bacterial pathogens in Iraq during 2021–2024 and examine their implications for empirical antimicrobial therapy and stewardship. We conducted a retrospective longitudinal analysis of aggregated national AMR surveillance data for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Staphylococcus aureus. Annual resistance proportions were evaluated across clinically relevant antimicrobials. Temporal change was characterised using absolute percentage-point changes and exploratory linear regression. Resistance trajectories were interpreted in relation to empirical treatment options and antimicrobial stewardship. The analysis included 92,338 organism records: 40,496 (43.9%) E. coli, 24,621 (26.7%) S. aureus, 18,223 (19.7%) K. pneumoniae and 8,998 (9.7%) P. aeruginosa. In 2024, ceftriaxone resistance reached 82.9% in E. coli and 65.2% in K. pneumoniae, while ciprofloxacin resistance was 55.4% and 57.9%, respectively. Meropenem resistance reached 37.4% in K. pneumoniae and 62.3% in P. aeruginosa. Conversely, resistance declined for amoxicillin–clavulanate in E. coli (83.5% in 2021 to 57.2% in 2024) and piperacillin–tazobactam in P. aeruginosa (46.4% to 32.9%). Several pathogen–antimicrobial combinations showed marked year-to-year variation, and no temporal trend remained statistically significant after false discovery rate correction. Resistance to several agents central to empirical therapy remains high in Iraq, while substantial carbapenem resistance constrains reliance on carbapenem escalation when resistance to other β-lactams is suspected. Heterogeneous trajectories indicate that empirical recommendations should not rely on single-year national antibiograms alone and support regular integration of national and local resistance surveillance into empirical treatment and antimicrobial stewardship strategies. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial NA ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study involved secondary analysis of de-identified, aggregated national antimicrobial resistance surveillance data provided by the Department of Clinical Pharmacy, Iraqi Ministry of Health, upon request. The dataset contained no patient-level or personally identifiable information, and the research team had no access to individual patient records. No additional specimens were collected and there was no direct involvement of patients or modification of clinical care. The analysis was conducted using existing aggregated surveillance data, and no individual informed consent was obtained because no identifiable or patient-level data were available to the research team. No separate research ethics approval was obtained for this secondary analysis. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability The data analysed in this study were derived from the Iraqi national antimicrobial resistance surveillance system. The underlying surveillance data are not publicly available because they are held by the responsible national health authorities and are subject to national data governance and access restrictions. Access to the data may be considered upon reasonable request and subject to approval by the relevant Iraqi authorities and applicable data governance requirements. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.09.30.26364389v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.10.01.26364514v1 "Shared and distinct effects of cognitive performance and mood on cognition-dependent instrumental activities of daily living in Parkinson disease")[Next ](https://www.medrxiv.org/content/10.64898/2026.09.29.26363255v1 "Multi-omics approach to map a clinically diverse large cohort with homozygous founder RAG1 p.C176F variant among Old Order Mennonites") Posted October 02, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.09.30.26364389v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/10/02/2026.09.30.26364389.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.09.30.26364389v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/10/02/2026.09.30.26364389.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Temporal Trends in Antimicrobial Resistance Among Clinically Important Pathogens in Iraq, 2021–2024: Implications for Empirical Antimicrobial Therapy Omeed Darweesh, Hemn Ahmed, Haidar Kadhim Al-Jawadi, Ramiar Kamal Kheder, Noor Najim Alwiswasi, Sarah Mohammed Hameed, Hemen Faik Mohammed, Amanj Ismael Baker Kurdi medRxiv 2026.09.30.26364389; doi: https://doi.org/10.64898/2026.09.30.26364389 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.30.26364389v1%26text%3DTemporal%2520Trends%2520in%2520Antimicrobial%2520Resistance%2520Among%2520Clinically%2520Important%2520Pathogens%2520in%2520Iraq%252C%25202021%25E2%2580%25932024%253A%2520Implications%2520for%2520Empirical%2520Antimicrobial%2520Therapy "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.30.26364389v1%26t%3DTemporal%2520Trends%2520in%2520Antimicrobial%2520Resistance%2520Among%2520Clinically%2520Important%2520Pathogens%2520in%2520Iraq%252C%25202021%25E2%2580%25932024%253A%2520Implications%2520for%2520Empirical%2520Antimicrobial%2520Therapy "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.30.26364389v1%26title%3DTemporal%2520Trends%2520in%2520Antimicrobial%2520Resistance%2520Among%2520Clinically%2520Important%2520Pathogens%2520in%2520Iraq%252C%25202021%25E2%2580%25932024%253A%2520Implications%2520for%2520Empirical%2520Antimicrobial%2520Therapy%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.30.26364389v1%26title%3DTemporal%2520Trends%2520in%2520Antimicrobial%2520Resistance%2520Among%2520Clinically%2520Important%2520Pathogens%2520in%2520Iraq%252C%25202021%25E2%2580%25932024%253A%2520Implications%2520for%2520Empirical%2520Antimicrobial%2520Therapy "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.09.30.26364389) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.09.30.26364389v1&count=horizontal&via=&text=Temporal%20Trends%20in%20Antimicrobial%20Resistance%20Among%20Clinically%20Important%20Pathogens%20in%20Iraq%2C%202021%E2%80%932024%3A%20Implications%20for%20Empirical%20Antimicrobial%20Therapy&counturl=www.medrxiv.org/content/10.64898/2026.09.30.26364389v1 "Tweet This") ## Subject Area * [Epidemiology ](https://www.medrxiv.org/collection/epidemiology) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (623) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (911) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (339) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4875) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (483) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (420) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (658) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1640) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16047) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (34) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1217) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7117) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (735) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1072) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5111) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1445) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1790) * [Hematology](https://www.medrxiv.org/collection/hematology) (589) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1353) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16349) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1183) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (676) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (156) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (728) * [Neurology](https://www.medrxiv.org/collection/neurology) (7370) * [Nursing](https://www.medrxiv.org/collection/nursing) (370) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1098) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1258) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1010
## Related Clinical Research

- [Species Diversity and Antimicrobial Resistance of Vibrio spp. in Farmed Pacific White Shrimp, Sout](https://medichelpline.com/clinical-feed/pubmed-42765590.md) (DOI: 10.1111/jfd.70292)
- [Genomic epidemiology and emerging antimicrobial resistance in Salmonella Paratyphi A from Australi](https://medichelpline.com/clinical-feed/medrxiv-13-genomic-epidemiology-and-emerging-antimicrobial-resistance-profiles-of.md)
- [Antibiotic-Resistant Bacteria and Antibiotic Residues Detected in Retail Red Meat in Bangladesh](https://medichelpline.com/clinical-feed/medrxiv-3-determination-of-antibiotic-resistant-bacteria-and-antibiotic-residues-in-red.md)
- [High prevalence of plasmid-borne ESBL and quinolone resistance in multidrug-resistant Escherichia](https://medichelpline.com/clinical-feed/biorxiv-3-high-occurrence-of-plasmid-mediated-quinolone-and-esbl-resistance-genes-among.md)
- [Tetrahydrocarbazole Antibiotic Potentiator Restores Multiple Drugs Against Resistant Klebsiella pn](https://medichelpline.com/clinical-feed/biorxiv-6-discovery-of-a-multi-class-antibiotic-potentiator-against-resistant-klebsiella.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.